Related Experiment Video
Updated: Jun 5, 2026
09:35
Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
Published on: May 10, 2017
Treatment options in trigeminal neuralgia
1Department of Neurology University of Duisburg-Essen Hufelandstrasse 55, 45122 Essen, Germany.
Therapeutic Advances in Neurological Disorders
|December 24, 2010
Summary
Trigeminal neuralgia (TN) affects 4.3 per 100,000 people annually, with women more commonly affected. Treatment challenges persist due to unclear causes and limited large-scale trials for optimal patient care.
Area of Science:
- Neurology
- Epidemiology
Background:
- Trigeminal neuralgia (TN) presents a significant challenge due to uncertain etiology and pathophysiology.
- The condition affects approximately 4.3 per 100,000 individuals annually, with a higher incidence observed in women.
Purpose of the Study:
- To review the current understanding of trigeminal neuralgia incidence, etiology, and treatment options.
- To address the challenge of selecting the most appropriate treatment for individual patients with TN.
Main Methods:
- Literature review of epidemiological data on TN incidence.
- Summary of current medical and invasive treatment modalities for TN.
- Discussion of the scarcity of large-scale, placebo-controlled clinical trials.
Main Results:
- TN incidence is 4.3/100,000 person-years, higher in women (5.9/100,000) than men (3.4/100,000).
- Preferred medical treatments include anticonvulsants, muscle relaxants, and neuroleptics.
- Invasive options like Gasserian ganglion percutaneous techniques, gamma knife surgery, and microvascular decompression are promising for refractory cases.
Conclusions:
- Effective management of trigeminal neuralgia is complex, requiring careful consideration of available therapeutic options.
- Further large-scale clinical trials are needed to guide treatment selection for TN patients.
- Invasive procedures offer viable alternatives for patients unresponsive to medical management.
Related Concept Videos
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...